To the Editor
Sukkarieh et al,1 answer to the question they raise in their recent article that there is a room for recommending vitamin D supplements in using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) in diabetic hypertensive and non-hypertensive patients.
The literature is full of data indicating a higher risk of many diseases such as immune mediated conditions, infections, diabetes mellitus, cardiovascular diseases, and cancer, if 25-hydroxyvitamin D (25[OH] D) levels are <20 ng/mL (50 nmol/L) and the risk decreases with higher level.2-5 There is little evidence for a linear causal association between vitamin D levels and risk of these diseases. There are no randomized controlled trials that show that adding vitamin D will lead to decreasing this risk or alter the outcome of these conditions. More research is needed to clarify the role of vitamin D in the prevention and management of extra skeletal diseases.
In conclusion, it is inappropriate to recommend vitamin D supplements in diabetic patients with or without hypertension using ACEi and ARBs medication. The Scientific Advisory Committee on Nutrition (SACN) has recommended a reference nutrient intake, the amount that is sufficient to meet the needs of 97.5% of the population, for vitamin D of 10µg (400 IU) a day to protect musculoskeletal health in people aged 4 years or older.6 Lastly, vitamin D intoxication may cause hypercalcemia with confusion, polyuria, and polydipsia, muscle weakness and pain, nephrocalcinosis and bone demineralization.
Reply from the Author
No reply received from the Author.
References
- 1.Sukkarieh HH, Bustami RT, Abdu MN, Khokhar AA, Salih AA, Abdalla HK. The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D? Saudi Med J. 2020;41:1083–1089. doi: 10.15537/smj.2020.10.25428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.World Health Organization. International Agency for Research on Cancer. Vitamin D and Cancer. IARC Working Group Reports. 5 Updated 2008 November. 2020 October 12. Available from URL: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf . [Google Scholar]
- 3.Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, Manson JE, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev. 2012;33:456–492. doi: 10.1210/er.2012-1000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science. 2012;337:1476–1478. doi: 10.1126/science.337.6101.1476. [DOI] [PubMed] [Google Scholar]
- 5.Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and extraskeletal actions of vitamin d: current evidence and outstanding questions. Endocr Rev. 2019;40:1109–1551. doi: 10.1210/er.2018-00126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Scientific Advisory Committee on Nutirion (SACN) 2016. [Accessed 2020 October 16]. Vitamin D and Health. Updated 2016 July. Available from URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/537616/SACN_Vitamin_D_and_Health_report.pdf .